- LSD doses between 5µg and 20µg were safe and well-tolerated, showing no significant negative effects on cognition, balance, or proprioception in older healthy participants.
- No increase in adverse effects or drug-related impairments compared to placebo, suggesting low-dose LSD is comparable to a harmless control treatment in terms of participant safety.
- Further studies into the therapeutic potential of LSD for cognitive decline, like Alzheimer’s disease, are warranted based on the positive results of safety and tolerability.
Introduction to the Study
This research involved a Phase I study aimed at assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of low-dose LSD in older healthy volunteers. The study enrolled 48 individuals with an average age of 63 and featured a double-blind, placebo-controlled, randomized design to ensure the reliability of its findings.
Study Goals and Methods
The primary objectives of the study involved confirming that various doses of LSD (5 µg, 10 µg, and 20 µg) did not negatively impact participants. Volunteers were randomly assigned to receive either LSD or a placebo on multiple occasions over a 21-day period. Safety assessments included monitoring for any adverse events, blood pressure, and cognitive evaluations.
Volunteer Selection and Safety Assessments
Participants were carefully screened to exclude those on central nervous system medications and those with significant medical histories that could interfere with the study. The safety assessments indicated no significant difference in adverse events between the LSD and placebo groups. Mild or moderate headaches were the primary reported side effect but did not lead to any discontinuation among participants.
Pharmacological Analysis
Pharmacokinetic analysis showed that LSD was efficiently absorbed, with drug levels measurable after doses were administered. The average half-life of LSD was consistent with previous studies. The variations in drug levels suggest that the repeated dosing regimen may lead to slightly inconsistent concentrations in different individuals over time.
Cognitive and Pharmacodynamic Assessments
Using the Cambridge Neuropsychological Test Automated Battery, no significant treatment effects were observed in cognitive functioning among the different dosing groups. Moreover, the results indicated that LSD did not cause any impairments in cognitive tasks, balance, or proprioceptive function, even at the maximum tested dose. Despite this, a dose-dependent increase in feelings of dizziness and “bad drug effects” were noted, which could have potential implications for future assessments of LSD’s therapeutic viability.
Discussion on Observations
The study confirmed that low doses of LSD do not impair cognitive functions in healthy older adults. Thus, the findings do not raise concerns regarding its safety; however, some individuals reported a decrease in vigilance, which was not detrimental to their cognitive task performance. The researchers emphasized future investigation into how these minor adverse effects can be managed, especially if LSD is to be explored as a therapeutic avenue for conditions like Alzheimer’s disease.
Conclusion and Future Directions
In summary, this Phase I trial demonstrates that low doses of LSD are well-tolerated by healthy older adults without causing cognitive impairment. The potential applicability of LSD in treating or preventing conditions such as Alzheimer’s disease opens the door for further research aimed at understanding its therapeutic mechanisms and addressing the context-dependent effects observed during the trial.
Read the full paper summary on Blossom.
